Boehringer Mannheim Gmbh

Roche Diagnostics Operations, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Erasmus Huber

Gerald F Sigler

Herbert Von Der Eltz

Eva Hoess

Raymond Hui

Christian Klein

Mitali Ghoshal

Ina Deras

Ronald Charles Hawley

Salvatore Joseph Salamone

John W Patterson

Allan R Dorn

Christine Markert-Hahn

Hans-Peter Josel

Richard Terry Root

Bruno Zink

Beatus Ofenloch-Haehnle

Sigrun Metz

Peter Kern

Christa Hubner-Parajsz

Ulrich Essig

Wolfgang Rollinger

Brigitte Drager

Werner Naser

Dieter Heindl

Hans-Georg Batz

Rupert Herrmann

Michael Schraeml

Uwe Kobold

Michael Gerg

Todd P Glancy

Thomas Meier

Klaus Muhlegger

Rudolf Vogel

Lili Arabshahi

Gunter Pappert

Michael Wiedmann

Leopold Von Proff

Frederic Donie

Roland Schenk

Ursula Klause

Dietmar Zdunek

Klaus Hirzel

Charles F Walter

Frank E Klein

Caroline Dorothea Hojer

Klaus Hallermayer

Konrad Kurzinger

Josef Dieckhoff

Susanne Feldmann

Angela Puhlmann

Apostolos Kyriatsoulis

Haijuan Li

The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as discloed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.

Biotin-specific monoclonal antibody and use thereof

Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies.

Protease inhibitor conjugates and antibodies useful in immunoassay

Saquinavir conjugates and antibodies useful in immunoassay

The present invention provides a method for the measurement of an analyte in biological samples whereby an uncompetitive inhibitor is coupled to a ligand and utilized in a homogeneous assay. The analyte can be a drug or drug derivative, hormone, polypeptide, or oligonucleotide. The present invention also provides novel compounds, assay reagents and packaged kits useful for performing such measurements.

Conjugates of mycophenolic acid

The present invention relates to a chemical compound comprising a light emitting moiety precursor and a precursor of a leaving group, bound to each other by an amide or by an ester bond and characterized in that the leaving group precursor upon oxidation is converted into the leaving group. The invention also relates to compounds additionally comprising a coupling group to the use of such compounds for labeling of biomolecules and more generally to the use of such compounds in chemiluminescence detection procedures.

Compounds for chemiluminescense procedures

Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for HIV protease inhibitors. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group common to all HIV protease inhibitors, e.g., saquinavir, nelfinavir, indinavir, amprenavir, ritonavir, lopinavir, and atazanavir.

A method for quantifying an HIV protease inhibitor in a sample includes combining HIV protease, a conjugate comprising an HIV protease inhibitor analog, and a sample suspected of containing an HIV protease inhibitor. The HIV protease and the conjugate are capable of forming a detectable complex. The method also includes measuring the amount of the detectable complex, and relating the amount of the detectable complex to a concentration of the HIV protease inhibitor in the sample.

Method, assay, and kit for quantifying HIV protease inhibitors

Conjugates of uncompetitive inhibitors of inosine monophosphate dehydrogenase

Enzyme inhibition immunoassay

The invention concerns activated amphetamine derivatives, a process for their production as well as their use for producing immunogens or detection conjugates carrying amphetamine groups. A further subject matter of the invention are new conjugates carrying amphetamine groups, a process for the production thereof as well as their use for the production of antibodies or for the determination of amphetamine or derivatives thereof.

Activated amphetamines

The invention addresses new photo-activatable biotin derivatives having the formula I ##STR1## wherein R=�(CH.sub.2).sub.n --O.sub.m !.sub.q --�(CH.sub.2).sub.r --O.sub.s !.sub.t --(CH.sub.2).sub.p

Photo-activatable biotin derivatives and their use to reduce

A method for determining collagen degradation products in a body fluid sample using a non-competitive or competitive immunoassay is disclosed, the method comprising incubating the body fluid sample with an amount of antibody which specifically reacts with the amino acid sequence of SEQ ID NO. 2 of collagen l or a fragment thereof, and determining the collagen degradation products bound to the amount of the antibody. A kit for such a method is also disclosed.

Immunoassay for the detection of collagen I

Growing community of inventors

Finning, Germany

Erasmus Huber